New cocktail of drugs shows promise for tough bile duct cancer
NCT ID NCT07328802
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests a combination of sintilimab (an immunotherapy), bevacizumab (a targeted therapy), and chemotherapy (albumin-bound paclitaxel plus gemcitabine) as a first treatment for people with advanced bile duct cancer that cannot be surgically removed. The study aims to see how well the combination shrinks tumors and controls the disease. About 25 participants will receive the drugs intravenously every three weeks, with chemotherapy for up to 8 cycles followed by maintenance therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sintilimab, bevacizumab, albumin-bound paclitaxel, and gemcitabine
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for people with advanced cholangiocarcinoma, potentially improving tumor shrinkage and survival.
- What could go wrong
- This is a small, early-phase trial with only 25 participants, so results may not apply broadly. The combination of drugs can cause significant side effects, and the study may not show enough benefit to move forward.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORR,OS,PFS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
the Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China